Inotiv, Inc. (NOTV)

Recent Quarterly Results

Source: Company filings

Price Chart

Inotiv, Inc. (NOTV) stock price: $0.58 (+0.04, +7.73%)

Why Bull

• •Insider buying has increased recently, indicating confidence from leadership in the company's future.
• •Community sentiment has turned positive, with discussions highlighting Inotiv's strong pipeline of services and innovations.
• •Analysts are optimistic about Inotiv's potential due to recent contract wins and partnerships that enhance its market position.
• •The overall market perception has shifted favorably with growing interest in biotech and life sciences, benefiting Inotiv.

Why Bear

• •Recent community discussions reflect concerns about regulatory challenges that could impact Inotiv's operations.
• •Some investors are wary of the company's past performance and ongoing volatility in the biotech sector.
• •There are fears regarding competition in the market, with new entrants potentially threatening Inotiv's market share.
• •Market sentiment remains cautious, with some analysts highlighting the need for more consistent growth to regain investor trust.

• Earnings Scheduled For February 9, 2026
  benzinga · Feb 9, 2026
• 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
  benzinga · Nov 19, 2025
• 12 Health Care Stocks Moving In Tuesday's After-Market Session
  benzinga · Nov 18, 2025
• Top 3 Health Care Stocks Which Could Rescue Your Portfolio In November
  benzinga · Nov 18, 2025

Rationale

AI-generated technical analysis for NOTV including trend direction, momentum, and pattern recognition.

What to Watch

Key support and resistance levels, volume signals, and upcoming events.

Risk Management

Position sizing, stop-loss levels, and risk-reward assessment.

Set your price target for Inotiv, Inc. (NOTV), choose a timeframe, and track your prediction accuracy.

Current price: $0.58

Score Factors

• Revenue Growth 4/100

  Revenue grew only 4.5% YoY, suggesting the company is in a slower growth phase.

• Gross Margin 6/100

  Gross margin of 23.5% is acceptable but leaves limited room for R&D and marketing investment.

• Operating Leverage 4/100

  Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.

• Cash Runway 5/100

  Cash position data is currently unavailable for this company.

• R&D Intensity 5/100

  R&D spending data is currently unavailable for this company.

• Insider Activity 3/100

  Net insider selling of -$1.27M may indicate reduced confidence or routine diversification by executives.

• Short Interest 5/100

  Float and volume data unavailable for liquidity analysis.

• Price Momentum 0/100

  No bullish technical signals detected. The stock lacks upward price momentum currently.

• News Sentiment 5/100

  No sentiment data available

What does this score mean?

The MoonshotScore rates NOTV's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

What does Inotiv, Inc. do?

Inotiv, Inc. is a contract research organization (CRO) and provider of research products that supports the drug discovery and development efforts of pharmaceutical, chemical, and medical device companies. The company operates through two segments: Contract Research Services, which offers a range of preclinical testing and regulatory compliance services, and Research Products, which designs, develops, and markets in vivo sampling systems and analytical instruments. Inotiv's comprehensive solutions help its customers accelerate research timelines, reduce costs, and navigate the complex regulatory landscape.

Is NOTV stock a good buy?

NOTV stock presents a mixed investment profile. While the company operates in a growing industry and offers comprehensive services, its negative profit margin and high beta raise concerns. Investors should consider the potential for future earnings growth and the company's ability to capitalize on growth opportunities. A thorough analysis of Inotiv's financial performance, competitive positioning, and growth strategy is essential before making an investment decision. The small market cap also indicates higher risk.

What are the main risks for NOTV?

The main risks for Inotiv include its negative profit margin, which indicates financial instability, and its high beta, which suggests significant stock price volatility. Intense competition from other CROs and analytical instrument providers poses a threat to the company's market share. Regulatory changes in the pharmaceutical industry could also impact demand for Inotiv's services. Additionally, economic downturns could reduce research spending and negatively affect the company's revenue.

Is NOTV a good stock to buy?

Whether NOTV is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.

What is the NOTV MoonshotScore?

The MoonshotScore for NOTV is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.

How often is NOTV data updated?

NOTV stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to NOTV is aggregated continuously from premium financial news sources throughout the day.

What are the growth catalysts for NOTV?

Growth catalysts for Inotiv, Inc. (NOTV) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes Inotiv, Inc.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.

Who are NOTV's main competitors?

Inotiv, Inc. (NOTV) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether NOTV has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.

What do analysts say about NOTV?

Wall Street analyst coverage for NOTV includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.

What is NOTV's market cap?

Market capitalization (market cap) for NOTV is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows NOTV's current market cap alongside enterprise value and other valuation metrics.

How has NOTV stock performed recently?

NOTV's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing NOTV's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.

What are the risks of investing in NOTV?

Key risk categories for NOTV include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures NOTV's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.

Are insiders buying or selling NOTV?

Insider trading activity for NOTV tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.

Is NOTV a good stock for beginners?

Inotiv, Inc. (NOTV) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.

How risky is NOTV for first-time investors?

Every stock carries risk, including Inotiv, Inc. (NOTV). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like NOTV.